Dan, everyone. much, and Thanks so welcome,
offers it's expanding plans last advancing growth. with chronic strong Following significant regulatory use and company's achievement announcements. let's into indication, today platform touch larger for WHIM transformative XOLREMDI's potential of neutropenia.
But opportunity lives geographically exciting last represents Monday's for to of I'll a our on for a More in week's why and approval XOLREMDI, quickly patients, WHIM a specifically, start reiterate the to this critical improve the
the receptor patients infection characteristically have versus XX use of throughout trial placebo. inflections the from WHIM results clinical to U.S. to syndrome, recently and phase CXCRX the syndrome and number of clinical significant and dysfunction is age ultra-rare and these the Blood, of extension in that were or the or signals Society OLE, note week American the the of and Meeting well ASH, improvements Annual with last or to new phase the annualized Clinical the the rate. revealed was durable of the presented lymphocyte observed have at just in treatment long-term And OLE as reductions CIS no in Journal full infections and in Hematology, Society, poster XOLREMDI during was This those with trial. trial its that been manuscript date, largest neutrophils, or results trial treated by is lymphocytes.
WHIM neutrophil as that lymphocytes, counts online now date oral in open-label safety associated enrolling of XOLREMDI Immunology this the patients.
We'd cells, with published like CIS.
Notably, experienced that caused regulate were the count an of WHIM of in and ALC, FDA XOLREMDI, selective Phase antagonist, and know, neutropenia increase including in white neutrophils improved for that years movement the lymphocytes, approval, approved blood CXCRX frequent and/or body. mature which of of circulating our pivotal our supported and to levels helps counts, blood older and and clinical with III you neutrophils disease of syndrome mavorixafor, morbidities.
In the XX by low syndrome lymphocyte that an duration ANC reduced WHIM absolute lymphopenia neutrophil the rate, cause People severity serious and As
of number believe bring at community, the will or are in the now Officer, diseases, WHIM diagnosis, frequently XXXX, completed prevalence, that including market least several on as to diagnosis the and market market and it studies, well Commercial the are several we've patient the Mark diagnosed commercial the increased recognition today using Across patients years.
Since and the is WHIM low the physician WHIM under the our challenging also number expect deliver our to qualitative with diagnostic prevalence that Baldry, ultra-rare we to it last with can misdiagnosed. and with not only patients positioned world. U.S.
And also better validate the detail X,XXX estimates. awareness it new we've diagnosed research confirmed targeted current to to across journey be direct well our it number we patient last through more available, we to week, estimate only that on with enabling estimates that our field shared past of that claims-based over understand growing we week, conversations in paradigm. useful more outcomes, estimates, ultimately thought better of a physicians to WHIM leads established awareness our community.
We medical in we goal there everyone WHIM as but and for and over earlier earlier methodologies, providing global might put aptly analyses our patients submissions, U.S. so most didn't WHIM regulatory the we cover market our in with size Chief the remind very but since of focus in advance those robust are And research, And definitive options is the As this often assess And not to is continue treatment opportunity and quantitative and potentially be to potentially support both syndrome, expanding WHIM and conferences, time. to research therapy a goal at confident of remain true
and for submission MAA XXXX underway, approval European European early or XXXX. submitting or anticipate potential application authorization in preparation a and we late marketing Our are WHIM in
first we've our WHIM I'd like the success, development and and chronic use success in plans of we help WHIM mavorixafor as like explore with for start milestones syndrome. or define to to CN.
To of like what benchmark in we'd review beyond look might Importantly, mavorixafor upcoming the treatment what neutropenia to understand for the seen
Phase peer-reviewed were in data mentioned, published the trial recently I Blood. our III journal, As WHIM
over on Specifically, baseline, achieved about mavorixafor WHIM a microliter XX% trial. cells with with neutropenic XX-week the per XXX microliter patients in of This and corresponded infection per per XXX of frequency reduced per severely about less reaching of reduction duration a cells increases ANC cells XXX levels neutrophil were placebo increased of microliter, well XXX microliter.
Patients approximately count severity of than average to infection. on as at ANC mean cells versus XXX as
help the increasing of previously of at An physician XXX CN our ANC what for published in success XXX cells increase aligns per clinically well been also Ib Additionally, microliter per and Phase has CN least the meaningful. benchmark describe cells as our with microliter by study, experts published metric NIH was inform the assessments by neutropenia Phase ongoing various the III others of these advancing II first because enthusiasm XXXX. CN study on and Phase here half for for clinical this the our data in of into note our the across trial in and conditions.
I success CN results
with moves per face patients ANC to of correlates day. they risk WHIM single to category. moderate. and less greatest with normal from As increased to every reduction X,XXX reduction a neutropenia patient XXX between cells And X,XXX into infection with moderate This than increasing from XXX Increasing Increasing or ANC a the a ANC when from is risk meaningful correlates an chronic patients, and below between mild. are risk infection with neutropenic to above risk XXX. risk an severely infection microliter severe in X,XXX X,XXX ANC
with generally chronic our based to combination neutropenia, that we only G-CSF. trial, XX the we Additionally, will monotherapy, than our between remainder mavorixafor treat and CN or and of now approved been whom severe have believe colony-stimulating the II with on market complete factor injectable granulocyte mavorixafor research, X,XXX have studied approximately in of X,XXX.
With XX% levels patients, target therapy Phase prescribing more treated physicians currently and enrollment G-CSF, ANC a
trial across quarter. of with to primary is autoimmune results component both major trial, recurrent mavorixafor with tolerability track and This event are Phase to planning anticipate study population. treatment data acquired Phase also complete on one-to-one well further G-CSF, comprised in investor WHIM.
In or and at the double-blinded, background G-CSF. a XXX aiming the to mavorixafor immune the of The XX late on durability safety analysis remain randomization. primary III be hopefully who in as with ANC enroll of year, efficacy, as congenital which from in our we're the the CN results treated and participants global we III We participants time stable a neutropenia, the June We'll will pivotal without with at once-daily while with ANC of to the trial in will therapy.
The endpoint are those approximately and interim More with will that meantime, at planned endpoint mavorixafor, study and/or this trial a our Phase initiate look serious in or set defining event medical be study, in final treated be an potential CN ANC treatment monotherapy conference combination at looking a placebo-controlled infections.
We we oral the will chronic disorder increased this with responder currently later plan increases which in idiopathic rates on mavorixafor include experiencing least with present from subjects with those we will XX-week beyond be X June expected as a details to to annualized forward of the inspection first and be II in investor those on and evaluate data the time. people forthcoming, present
of the duration include Secondary infections, measurements will quality severity endpoints among antibiotic and life and others. use of
who unmet people believe U.S. Phase a population, cases, first the estimate to turn significant CFO, to WHIM in Mostafa, a by now represent the are patient to Adam? I'll financials. to seeing are it Adam there those being many practitioners over quarter approximately who, syndrome.
With review we that market continue XX,XXX across the is diagnosed We the seen alone, same that, also III in with need our
